We are live on ! Find out more
FTH icon

Faeth Therapeutics
FTH

26 hedge funds and large institutions have $4.71M invested in Faeth Therapeutics in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

298% more capital inflows, than outflows

Capital inflows: $1M | Capital outflows: $252K

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

4% more funds holding

Funds holding: 25 → 26 (+1)

1.57% more ownership

Funds ownership: 8.56% → 10.13% (+1.6%)

14% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 7

Holders
26
Holders Change
+1
Holders Change %
+4%
% of All Funds
0.41%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
6
Reduced
7
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NM
Newtyn Management
New York
+$571K
2
Morgan Stanley
Morgan Stanley
New York
+$190K
3
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$130K
4
Bank of America
Bank of America
North Carolina
+$61.2K
5
Millennium Management
Millennium Management
New York
+$4.38K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$70.2K
2
Western Standard LLC
Western Standard LLC
California
-$68.7K
3
Virtu Financial
Virtu Financial
New York
-$39K
4
E
Ergoteles
New York
-$27.9K
5
Two Sigma Investments
Two Sigma Investments
New York
-$23.4K

FTH Hedge Fund Activity: Q1 2023 in Review

26 of the 6,289 institutional investors tracked by Wall St. Rank reported a position in Faeth Therapeutics (FTH) for Q1 2023, worth a combined $4.71M — up 20% from $3.92M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new FTH positions and 3 closed out — a net gain of 1 holder — while 6 added to existing stakes and 7 trimmed.

The largest buyer was Newtyn Management, adding an estimated $571K. The largest seller was Renaissance Technologies, cutting an estimated $70.2K.

  • 26 institutional investors held Faeth Therapeutics (FTH) as of Q1 2023, up from 25 in Q4 2022.
  • Funds reported $4.71M of Faeth Therapeutics stock for Q1 2023, up 20% quarter-over-quarter.
  • 4 funds opened new Faeth Therapeutics positions in Q1 2023 and 3 closed out, a net change of +1 holder.
  • The largest Faeth Therapeutics buyer in Q1 2023 was Newtyn Management, an estimated $571K added.
  • The largest Faeth Therapeutics seller in Q1 2023 was Renaissance Technologies, an estimated $70.2K sold.

Based on aggregated 13F filings for Q1 2023.